Peer-reviewed veterinary case report
COX-2 levels and survival in dogs after kidney cancer surgery
By Carvalho, S et al.·Published in Veterinary and comparative oncology·2017·Department of Clinical Sciences and Services, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy.
- Species:
- dog
Plain-English summary
A group of dogs with kidney tumors (renal cell carcinoma) underwent surgery to remove the affected kidney. After surgery, some dogs received additional treatment, and researchers looked at factors like COX-2 expression and tumor characteristics to see how they affected survival. They found that dogs with lower COX-2 scores and lower mitotic indices (a measure of how quickly the cancer cells were dividing) had significantly longer survival times. This information could help veterinarians better predict outcomes for dogs with this type of cancer after surgery.
People also search for: dog kidney cancer prognosis · renal cell carcinoma treatment in dogs · COX-2 score and dog survival
Abstract
Limited veterinary literature is available regarding prognostic markers for canine renal cell carcinoma (CRCC). We retrospectively evaluated COX-2 expression, histological and clinical features associated with prognosis of CRCC. Sixty-four cases post-nephrectomy were included, 54 had histopathological assessment and 30 had COX-2 immunostaining performed. Eight dogs (13%) had metastatic disease at initial diagnosis. Twenty-seven dogs (42%) received adjuvant therapy after nephrectomy. On univariate analysis, COX-2 expression, mitotic index (MI), histologic type, vascular invasion, neoplastic invasiveness and metastasis at diagnosis were significantly associated with overall median survival time (MST). COX-2 score (COX-2 score > 3 MST 420 days versus 1176 days if COX-2 score <3; P = 0.011) and MI (MI > 30 MST 120 days versus 540 days for MI < 30; P = 0.003) were the only variables associated with CRCC outcome on multivariate analysis. The addition of MI and COX-2 immunostaining to standard histopathological evaluation would help predicting outcome in CRCC patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27578604/